FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1562-1564 April 8, 2004 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cannon, C. P. PubMed Citation

In the management of atherosclerotic vascular disease, statin drugs have already surpassed all other classes of medicines in reducing the incidence of the major adverse outcomes of death, heart attack, and stroke. A decade ago, their effectiveness was first demonstrated by the results of the Scandinavian Simvastatin Survival Study (4S), a trial that provided definitive evidence of the benefit of simvastatin, as compared with placebo, in improving survival.¹ By 1996, statins were dubbed "miracle drugs," and their underuse was duly noted.² Prominent scientists in the field even speculated that heart attacks might be "gone with the century."³ For the most . . . [Full Text of this Article]

Source Information

From the Cleveland Clinic Lerner College of Medicine and the Department of Cardiovascular Medicine, Cleveland Clinic Foundation — both in Cleveland.



This editorial was published at www.nejm.org on March 8, 2004.

Address reprint requests to Dr. Topol at the Cleveland Clinic Foundation, 9500 Euclid Ave., Desk F25, Cleveland, OH 44105, or at topole@ccf.org.

Related Letters:

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
van der Harst P., Voors A. A., van Veldhuisen D. J., Miller M., Gotto A. M. Jr., Paradis J.-M., LeLorier J., Auer J., Weber T., Eber B., Cannon C. P., Braunwald E.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:714-717, Aug 12, 2004. Correspondence

This article has been cited by other articles:

• Scott, D., Blizzard, L., Fell, J., Jones, G. (2009). Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 102: 625-633 [Abstract] [Full Text]  
• Kromer, A., Moosmann, B. (2009). Statin-Induced Liver Injury Involves Cross-Talk between Cholesterol and Selenoprotein Biosynthetic Pathways. Mol. Pharmacol. 75: 1421-1429 [Abstract] [Full Text]  
• SHISHEHBOR, M. H., HAZEN, S. L. (2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine 76: 37-44 [Abstract] [Full Text]  
• Klopfleisch, S., Merkler, D., Schmitz, M., Kloppner, S., Schedensack, M., Jeserich, G., Althaus, H. H., Bruck, W. (2008). Negative Impact of Statins on Oligodendrocytes and Myelin Formation In Vitro and In Vivo. J. Neurosci. 28: 13609-13614 [Abstract] [Full Text]  
• Lee, S. J., Qin, H., Benveniste, E. N. (2007). Simvastatin inhibits IFN-{gamma}-induced CD40 gene expression by suppressing STAT-1{alpha}. J. Leukoc. Biol. 82: 436-447 [Abstract] [Full Text]  
• Goldman, D. P., Joyce, G. F., Zheng, Y. (2007). Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health. JAMA 298: 61-69 [Abstract] [Full Text]  
• Sipahi, I., Tuzcu, E. M., Wolski, K. E., Nicholls, S. J., Schoenhagen, P., Hu, B., Balog, C., Shishehbor, M., Magyar, W. A., Crowe, T. D., Kapadia, S., Nissen, S. E. (2007). {beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. ANN INTERN MED 147: 10-18 [Abstract] [Full Text]  
• Kaul, P. (2007). Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?. Eur Heart J 0: ehm168v1-2 [Full Text]  
• Yuan, G., Al-Shali, K. Z., Hegele, R. A. (2007). Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176: 1113-1120 [Abstract] [Full Text]  
• Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., Braunwald, E. (2006). Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. J Am Coll Cardiol 48: 438-445 [Abstract] [Full Text]  
• Mittleman, M. A. (2006). A 39-year-old woman with hypercholesterolemia.. JAMA 296: 319-326 [Abstract] [Full Text]  
• Arora, M., Chen, L., Paglia, M., Gallagher, I., Allen, J. E., Vyas, Y. M., Ray, A., Ray, P. (2006). Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc. Natl. Acad. Sci. USA 103: 7777-7782 [Abstract] [Full Text]  
• Kotti, T. J., Ramirez, D. M. O., Pfeiffer, B. E., Huber, K. M., Russell, D. W. (2006). Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. USA 103: 3869-3874 [Abstract] [Full Text]  
• Dunn, S. E., Youssef, S., Goldstein, M. J., Prod'homme, T., Weber, M. S., Zamvil, S. S., Steinman, L. (2006). Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. JEM 203: 401-412 [Abstract] [Full Text]  
• Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., Braunwald, E., for the PROVE IT-TIMI 22 Investigators, (2005). Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol 46: 1411-1416 [Abstract] [Full Text]  
• Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., Walters, E. E. (2005). Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593-602 [Abstract] [Full Text]  
• Hawk, E., Viner, J. L. (2005). Statins and Cancer -- Beyond the "One Drug, One Disease" Model. NEJM 352: 2238-2239 [Full Text]  
• Rosen, M., Haglund, B. (2005). From healthy survivors to sick survivors -- implications for the twenty-first century. Scand J Public Health 33: 151-155 [Abstract]  
• Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., Ganz, P., the Reversal of Atherosclerosis with Aggressive Li, (2005). Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. NEJM 352: 29-38 [Abstract] [Full Text]  
• Pandey, D. K., Gorelick, P. B. (2005). Should Statin Agents Be Administered to All Patients With Ischemic Stroke?. Arch Neurol 62: 23-24 [Full Text]  
• (2004). LDL After ACS: Is Lower Better?. Journal Watch Cardiology 2004: 2-2 [Full Text]  
• Nissen, S. E. (2004). High-Dose Statins in Acute Coronary Syndromes: Not Just Lipid Levels. JAMA 292: 1365-1367 [Full Text]  
• van der Harst, P., Voors, A. A., van Veldhuisen, D. J., Miller, M., Gotto, A. M. Jr., Paradis, J.-M., LeLorier, J., Auer, J., Weber, T., Eber, B., Cannon, C. P., Braunwald, E. (2004). Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. NEJM 351: 714-717 [Full Text]  
• (2004). LDL After ACS: Is Lower Better?. Journal Watch Cardiology 2004: 1-1 [Full Text]  
• (2004). Lipid-Lowering After Acute Coronary Syndromes -- Intensive Is Better. JWatch General 2004: 1-1 [Full Text]